Literature DB >> 17093086

Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration.

Jun Peng1, Lin Xie, Fang Feng Stevenson, Simon Melov, Donato A Di Monte, Julie K Andersen.   

Abstract

The murine mutant weaver (gene symbol, wv) mouse, which carries a mutation in the gene encoding the G-protein inwardly rectifying potassium channel Girk2, exhibits a diverse range of defects as a result of postnatal cell death in several different brain neuron subtypes. Loss of dopaminergic nigrostriatal neurons in the weaver, unlike cerebellar granule neuronal loss, is via a noncaspase-mediated mechanism. Here, we present data demonstrating that degeneration of midbrain dopaminergic neurons in weaver is mediated via neuroinflammation. Furthermore, in vivo administration of the anti-inflammatory agent minocycline attenuates nigrostriatal dopaminergic neurodegeneration. This has novel implications for the use of the weaver mouse as a model for Parkinson's disease, which has been associated with increased neuroinflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093086      PMCID: PMC6674792          DOI: 10.1523/JNEUROSCI.3447-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  15 in total

Review 1.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

Review 2.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

3.  Minocycline causes widespread cell death and increases microglial labeling in the neonatal mouse brain.

Authors:  J Alex Strahan; William H Walker; Taylor R Montgomery; Nancy G Forger
Journal:  Dev Neurobiol       Date:  2016-10-14       Impact factor: 3.964

Review 4.  Prospects for minocycline neuroprotection.

Authors:  Jennifer M Plane; Yan Shen; David E Pleasure; Wenbin Deng
Journal:  Arch Neurol       Date:  2010-08-09

Review 5.  Therapeutic Strategies for Immune Transformation in Parkinson's Disease.

Authors:  Maamoon Saleh; Milica Markovic; Katherine E Olson; Howard E Gendelman; R Lee Mosley
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

6.  Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess.

Authors:  Tammy Kielian; Nilufer Esen; Shuliang Liu; Nirmal K Phulwani; Mohsin M Syed; Napoleon Phillips; Koren Nishina; Ambrose L Cheung; Joseph D Schwartzman; Jorg J Ruhe
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

7.  Antioxidant-Rich Fraction of Urtica dioica Mediated Rescue of Striatal Mito-Oxidative Damage in MPTP-Induced Behavioral, Cellular, and Neurochemical Alterations in Rats.

Authors:  Rohit Bisht; Bhuwan Chandra Joshi; Ajudhiya Nath Kalia; Atish Prakash
Journal:  Mol Neurobiol       Date:  2016-09-13       Impact factor: 5.590

Review 8.  The role of anti-inflammatory agents in Parkinson's disease.

Authors:  Edith G McGeer; Patrick L McGeer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation.

Authors:  Jun Peng; Fang Feng Stevenson; May Lin Oo; Julie K Andersen
Journal:  Free Radic Biol Med       Date:  2008-11-07       Impact factor: 7.376

Review 10.  Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.

Authors:  Mariza Bortolanza; Glauce C Nascimento; Sergio B Socias; Diego Ploper; Rosana N Chehín; Rita Raisman-Vozari; Elaine Del-Bel
Journal:  J Neural Transm (Vienna)       Date:  2018-08-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.